Healthcare Services Company Research Reports

Healthcare services represent a huge segment of the medical industry. Companies involved in the healthcare services market provide testing or treatment of a disease or dysfunction. All services are implemented by professionals in medicine, nursing, dentistry such as public health practitioners, community health workers, etc..

Kindred Healthcare Inc., Patient Home Monitoring Corp., Aikchol Hospital Public Co. Ltd., America Service Group Inc., Apollo Hospitals Enterprise Ltd., Coventry Health Care Inc. are among top companies that participate in the health services market.

The Catalogue offers innumerable research reports dedicated to the companies active in the healthcare services market. The research reports include profiles of large-cap, middle-sized and small companies. Data on companies’ historical development, financial performance, marketing strategies and structure are offered in the reports. Information on market trends, opportunities, barriers and igniters can be found in the research reports too.

Found 590 publications
Global Stem Cell Partnering 2010-2016: Deal trends, players, financials and forecasts US$ 2,995.00

... Stem Cell deals Access to Stem Cell contract documents Leading Stem Cell deals by value since 2010 Most active Stem Cell dealmakers since 2010 In Global Stem Cell Partnering 2010-2016 ...

Nov, 2016 370 pages
Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts US$ 2,995.00

... Case studies of real-life Molecular Diagnostics deals Access to Molecular Diagnostics contract documents Leading Molecular Diagnostics deals by value since 2010 Most active Molecular Diagnostics dealmakers since 2010 In Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and ...

Sep, 2016 447 pages
Global In Vitro Diagnostics 2010-2016: Deal trends, players, financials and forecasts US$ 2,995.00

... In Vitro Diagnostics deals Access to In Vitro Diagnostics contract documents Leading In Vitro Diagnostics deals by value since 2010 Most active In Vitro Diagnostics dealmakers since 2010 In Global In Vitro Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals ...

Nov, 2016 660 pages
Vitmark-Ukraine SP TOV in Health and Wellness (Ukraine) US$ 572.00

Vitmark-Ukraine popularizes and actively promotes the ideas of healthy development of the consumers and society as a whole. Over the forecast period, Vitmark ... company profiles. Product coverage: Health and Wellness by Category, Health and Wellness by Prime Positioning, Health and Wellness by Type. Data ...

Jul, 2015 2 pages
Rozmay PP in Health and Wellness (Ukraine) US$ 572.00

Rozmay PP plans to increase its range with new kinds of diabetic products ... of snapshot company profiles. Product coverage: Health and Wellness by Category, Health and Wellness by Prime Positioning, Health and Wellness by Type. Data coverage: market ...

Jul, 2015 2 pages
OTCPharm OAO in Consumer Health (Russia) US$ 150.00

... companies in consumer health, OTCPharm is set to build upon the success of its numerous brands. Further investment in research and development, as well as the marketing of consumer health solutions ... . Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management and ...

Sep, 2016 2 pages
Auriga International SA in Beauty and Personal Care (Belgium) US$ 150.00

... closely with Belgian universities regarding research and development, Auriga International will continue to focus on rejuvenation of face, cellulite and liposuction ... Shower, Colour Cosmetics, Deodorants, Depilatories, Fragrances, Hair Care, Mass Beauty and Personal Care, Men's Grooming, Oral Care, Oral ...

May, 2016 2 pages
Akvion ZAO in Consumer Health (Russia) US$ 572.00

Akvion ZAO has stated that the development of ... Moreover, the company is open to partnerships through exclusive distribution in Russia and the CIS. Euromonitor International Local Company ... Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors ...

Jul, 2015 2 pages
Akrikhin OAO in Consumer Health (Russia) US$ 150.00

Akrikhin aims to continue with its strategy of developing and producing its ... reinforce the company’s position as one of the major domestic players in consumer health in Russia over the forecast period. Euromonitor International Local Company Profiles ...

Sep, 2016 2 pages
Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts US$ 2,995.00

... access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies DESCRIPTION The Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials ...

Sep, 2016 660 pages
Hadasit Medical Research Services & Development Ltd - Product Pipeline Review - 2015 US$ 1,500.00 US$ 1,200.00

... pipeline projects Latest company statement Latest news and deals relating to the Hadasit Medical Research Services & Development Ltd’s pipeline products Reasons to buy Evaluate Hadasit Medical Research Services & Development Ltd ...

Jul, 2015 24 pages
Global Pediatrics Partnering 2010-2016: Deal trends, players and financials US$ 2,995.00

... Pediatrics deal contract documents Comprehensive access to over 3500 Pediatrics deal records The leading Pediatrics deals by value since 2010 Most active Pediatrics dealmakers since 2010 In Global Pediatrics Partnering 2010 to 2016, available deals ...

Nov, 2016 500 pages
TOWA - Performance Will Outcast New ‘Mid Term Plan’ US$ 140.00 US$ 119.00

... Towa’s MTP announcement, it has projected single digit revenue growth and assumed there will not be any ‘New Major Reform’ by Govt to enhance ... in dispensing fee and incentives to doctors will boost Towa’s revenue (as 90%+ its revenue from these two segments), 2) Towa management is taking the right decision ...

Nov, 2011 7 pages
DAIICHI SANKYO - Denosumab Approval In Japan: Will Contribute Bottom Lines Despite Partnering! US$ 90.00 US$ 76.50

Daiichi Sankyo’s announced its approval of first antibody Ranmark (denosumab, fully human anti-RANKL antibody, in-licensed from Amgen, Co-promoted ... from multiple myeloma and bone metastases from solid tumors in Japan. Approval was based on global clinical studies where it not only demonstrated ...

Jan, 2012 4 pages
1 2 3 4 5 >
Skip to top